Research Ethics Committee Reference Number	IRAS number	Full Name of Trial	Target number of patients available?	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Target date to recruit patients agreed?	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date trial closed to recruitment	Reason for the closure of the trial
11/LO/0537	75448	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	Number agreed	6	6	Date agreed	01/02/2013	5	24/11/2015	Recruitment finished
13/NW/0316	124757	Phase 4 trial comparing cumulative incidence of SCC after treatment + ingenol mebutate & imiquimod for multiple actinic keratoses on face &scalp. A multi-centre, randomised, two-arm, open label, active-controlled, parallel group, 36-month trial.	Number agreed	8	8	Date agreed	31/05/2015	10	31/03/2016	Recruitment finished
14/LO/1381	153109	Reformulated raltegravir q.d. (1200 mg) versus raltegravir b.i.d. (400 mg) in ART-naïve pts	Number agreed	5	5	Date agreed	30/04/2015	5	05/12/2015	Withdrawn by Sponsor
13/YH/0147	131219	A Randomized, Open Label, Multi-Centre, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Acute Alcoholic Hepatitis (AAH) Who Have Failed Steroid Therapy (incorporating VTI-210E as a follow-up registry)	Number agreed	4	4	Date agreed	31/08/2015	0	21/08/2015	Recruitment finished
14/EM/1070	159169	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults	Number agreed	1	1	Date agreed	01/10/2015	1	20/08/2015	Recruitment finished
14/SS/1048	154401	A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease	Number agreed	5	5	Date agreed	10/07/2015	5	01/03/2016	Recruitment finished
13/NI/0188	140146	A single-arm trial to evaluate the effectiveness of PCI of de novo 3-vessel disease applying the SYNTAX Score II with pressure wire functional assessment and IVUS guidance, using an everolimus-eluting stent with biodegradable	Range agreed	10	40	Date agreed	01/03/2016	6	08/09/2015	Recruitment finished
14/WM/1210	164208	A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects.	Number agreed	4	4	Date agreed	12/08/2015	11	29/01/2016	Recruitment finished
15/LO/0075	164748	A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects	Number agreed	5	5	Date agreed	01/03/2018	3	27/08/2015	Withdrawn by Sponsor
14/NE/1185	152820	Short duration of dual antiplatElet therapy with SyNergy® II everolimus eluting stent in patients Older than 75 years undergoing percutaneous coronary Revascularization. The SENIOR trial	Range agreed	15	40	Date agreed	30/06/2015	7	11/02/2016	Recruitment finished

13/EM/0348	122371	Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan® 0.01 % with ocular surface intolerance	Number agreed	6	6	Date agreed	30/04/2016	2	30/04/2016	Recruitment finished
14/NW/1531	165328	Comparative Testing of 3 mL TransFix/EDTA Vacumm Blood Collection Tubes (TVTs) and Cyto-Chex 5 mL Blood Collection Tubes (BCTs) Part 1: Equivalence Study	Number agreed	10	10	Date agreed	05/11/2015	13	19/04/2016	Recruitment finished
15/YH/0045	168195	ABLATOR Ablation Observational Registry	Range agreed	25	100	Date agreed	17/07/2017	36	22/02/2016	Recruitment finished
13/EE/0335	137965	COOL-AMI EU CASE SERIES CLINICAL STUDY: a single-centre case series clinical study to assess the feasibility of integrating therapeutic hypothermia(TH)using the ZOLL IVTM System as an adjuvant therapy in percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI)	Range agreed	5	7	Date agreed	28/02/2016	4	26/02/2016	Withdrawn by Sponsor
15/SC/0280	170452	Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The RE-CIRCUIT Trial)	Range agreed	9	20	Date agreed	31/08/2016	8	29/06/2016	Recruitment finished
15/LO/1239	184169	A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects.	Number agreed	5	5	Date agreed	30/09/2015	3	02/02/2016	Withdrawn by Sponsor
15/EE/0322	183313	A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P)	Number agreed	3	3	Date agreed	29/02/2016	1	10/06/2016	Recruitment finished
16/LO/0036	195359	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults	Number agreed	6	6	Not available / not agreed		5	10/06/2016	Withdrawn by Sponsor
16/LO/0026	195795	A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults	Number agreed	4	4	Not available / not agreed		3	22/06/2016	Withdrawn by Sponsor
16/LO/0039	195230	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV 1 Infected Subjects who are Virologically Suppressed	Number agreed	5	5	Not available / not agreed		2	03/06/2016	Withdrawn by Sponsor
13/NE/0336	137605	Trial of Proton Pump Inhibitors in Throat Symptoms	Number agreed	50	50	Date agreed	01/10/2017	9	12/02/2016	Withdrawn by Sponsor
12/NE/0198	100141	A Multicentre, Single-Blind, Randomised Parallel-Group Study to Assess the Short and Long-Term Efficacy of Certolizumab Pegol plus Methotrexate Compared with Adalimumab plus Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate	Range agreed	3	5	Not available / not agreed		1	10/05/2016	Withdrawn by Sponsor

13/SC/0279	124704	A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV1 Positive Subjects.	Number agreed	4	4	Not available / not agreed		4	16/06/2016	Recruitment finished